Lisa Newman, MD, MPH, FACS, FASCO, and Alan B. Astrow, MD, discuss the need for systemic therapy in women with microinvasive triple-negative breast cancer and more intensive adjuvant therapy in women with intermediate-risk hormone receptor-positive, HER2-negative breast cancer.
We traveled to Philadelphia, Pennsylvania, for a State of the Science Summit™ on Hematologic Malignancies, which featured insights from the University of Pennsylvania faculty.
We traveled to Chicago, Illinois, for a State of the Science Summit™ on Lung Cancer, which featured insights from the University of Chicago faculty.
We traveled to Raleigh, North Carolina, for a State of the Science Summit™ on Breast Cancer, which featured insights from the Duke Cancer Institute faculty.
We sat down with Ajai Chari, MD, and Sundar Jagannath, MD, both of Mount Sinai Hospital, to provide insight on controversial, but critical, questions regarding the merits of quadruplet versus triplet therapy in the newly diagnosed setting, the optimal maintenance approach in high-risk patients, and the data in support of and against initiating treatment in patients with smoldering multiple myeloma.
We traveled to Salt Lake City, Utah, for a State of the Science Summit™ on Non–Small Cell Lung Cancer, which featured insights from the University of Utah and Intermountain Healthcare.
OncLive interviewed experts at the State of the Science Summits™ in October 2019 on what they wish more people knew in community practice that is not yet widespread.
The European Commission has approved the combination of avelumab and axitinib for the frontline treatment of adult patients with advanced renal cell carcinoma.
We traveled to Pittsburgh, Pennsylvania, for a State of the Science Summit™ on Ovarian Cancer, which featured insights from the University of Pittsburgh Medical Center faculty.
Ruxolitinib met the primary endpoint of the phase III REACH2 trial, improving the overall response rate at day 28 versus best available therapy in patients with in patients with steroid-refractory acute graft-versus-host disease.
In keeping up with the expanding breast cancer treatment armamentarium, we sat down with Jane L. Meisel, MD, and Aditya Bardia, MD, MPH, who shed light on emerging treatment strategies for patients with metastatic triple-negative breast cancer and discussed the optimal timing of genomic testing in women with progressive hormone receptor–positive disease.
Patients with metastatic gastric or gastroesophageal junction cancer had improved overall survival with TAS-102, irrespective of prior gastrectomy.
We traveled to Seattle, Washington, for a State of the Science Summit™ on Hematologic Malignancies, which featured insights from Seattle Cancer Care Alliance faculty.
We traveled to Milwaukee, Wisconsin, for a State of the Science Summit™ on Breast Cancer, which featured insights from key thought leaders at Carbone Cancer Center of the University of Wisconsin.
OncLive interviewed experts at the State of the Science Summits™ in September 2019 on anticipated research to be presented at the 2019 ESMO Congress.
OncLive interviewed experts at the State of the Science Summits in August 2019 on aspects of care in their field that they wish were publicized more.
Belantamab mafodotin met the primary endpoint of demonstrating a clinically meaningful overall response rate in patients with relapsed/refractory multiple myeloma, according to topline results from the phase II DREAMM-2 trial.
The FDA has granted a priority review designation to a supplemental new drug application for enzalutamide (Xtandi) for the treatment of men with metastatic hormone-sensitive prostate cancer.
OncLive interviewed experts at the State of the Science Summits in July 2019 on highly anticipated clinical trial results across tumor types.
Although immunotherapy has become an important modality for treating non–small cell lung cancer, the development of new strategies for targeting oncogenic drivers of disease in subgroups of patients is moving forward at a brisk pace.
Higher doses of anthracyclines are associated with increased risk of breast cancer in women who survived childhood cancer, regardless of whether they have mutations that predispose them to cancer.
A weekly regorafenib (Stivarga) dose-escalation strategy beginning at 80 mg and ending at 160 mg is an appropriate and potentially optimal approach for previously treated patients with metastatic colorectal cancer.
OncLive interviewed experts at the State of the Science Summits in June 2019 on research being conducted at their respective institutions.
The European Medicines Agency's Committee for Medicinal Products for Human Use has backed approval of talazoparib (Talzenna) for adult patients with HER2-negative locally advanced or metastatic breast cancer harboring germline BRCA1/2 mutations.
The NCCN has updated their clinical practice guidelines for the treatment of patients with colorectal cancer to include the regimen of encorafenib and binimetinib plus EGFR inhibition with either cetuximab or panitumumab as a Category 2a treatment recommendation for patients with BRAF V600E–mutant metastatic colorectal cancer, after failure of 1 or 2 lines of therapy for metastatic disease.
The FDA has approved the frontline combination of atezolizumab plus nab-paclitaxel for patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer.
A new drug application has been filed with the FDA for darolutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer. ​
Frontline maintenance therapy with olaparib significantly reduced the risk of disease progression or death versus placebo in patients with germline BRCA-mutated metastatic adenocarcinoma of the pancreas, according to findings from the phase III POLO trial.
A subcutaneous formulation of daratumumab is noninferior in inefficacy and pharmacokinetics compared with standard intravenous daratumumab in patients with relapsed/refractory multiple myeloma.
The phase III JAVELIN Ovarian 100 study exploring frontline avelumab in ovarian cancer has been ended after an independent panel determined the study would not meet its primary endpoint of progression-free survival.
